Most of what Grok says about Counting Stars is taken from the blog itself. It is a good summary, of course, and done in a ...

“90% of the (school) districts in Wisconsin already have a policy” banning cellphones during class time. The 90% figure comes from testimony by the Department of Public Instruction, which conducts an ...

In a report released today, Francois Brisebois from Oppenheimer reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...

Roth MKM analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $29 and keeps a Buy rating on ...

The case at hand is a good example of this. A curious fact is that Georgescu worked for the United Nations and was one of the ...

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have ...

Join us to hear from industry leaders on the current trends in student housing, higher-ed and university real estate development. Gain insight on which universities and college campuses in Los Angeles ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...

The US Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase Ib multiple ascending dose (MAD) clinical study of ...